Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting

20 Oct 2020

Abstract excerpt

We aimed to evaluate the therapeutic potential of the pan-FGFR inhibitor erdafitinib to treat dedifferentiated liposarcoma (DDLPS). FGFR expression and their prognostic value were assessed in a series of 694 samples of well-differentiated/dedifferentiated liposarcoma (WDLPS/DDLPS). The effect of erdafitinib-alone or in combination with other antagonists-on tumorigenicity was evaluated in vitro and in vivo. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac tumors and thrombi
Share to Histiocytic Disorders and Treatments
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33092134
DOI: 10.3390/cancers12103058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual TargetingPMID 33092134Read ↗

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read ↗

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitroSemantic proximity Read ↗

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.Semantic proximity Read ↗

Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression driversSemantic proximity Read ↗

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated LiposarcomaSemantic proximity Read ↗

Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.Semantic proximity Read ↗

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy SelectionSemantic proximity Read ↗

Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunitiesSemantic proximity Read ↗

Prognostic Implications of MDM2 and CDK4 Co-amplification in Liposarcoma: Insights from FISH analysis for Translational OncologySemantic proximity Read ↗

Targeting the MDM2-p53 pathway in dedifferentiated liposarcomaSemantic proximity Read ↗

Clinical and Molecular Spectrum of LiposarcomaSemantic proximity Read ↗

Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.